Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
$0.11
$0.11
$0.11
$0.11
$8.60M0.3168,634 shs1,500 shs
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$0.22
$0.22
$0.17
$0.40
$6.47M0.521,730 shsN/A
Lannett Company, Inc. stock logo
LCI
Lannett
$1.54
$0.64
$3.72
$7.38M0.9592,067 shs280,600 shs
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.90
-1.1%
$2.23
$1.86
$4.73
$21.91M1.0321,065 shs5,705 shs
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$2.58
+0.4%
$2.44
$1.67
$8.73
$36.38M1.23121,145 shs60,115 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
0.00%0.00%0.00%0.00%-15.38%
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
0.00%0.00%-6.36%-12.96%-40.61%
Lannett Company, Inc. stock logo
LCI
Lannett
0.00%0.00%0.00%0.00%0.00%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
+1.59%+1.59%-16.16%-16.52%-46.81%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
+10.78%+7.08%+4.05%+44.38%-42.51%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
1.9476 of 5 stars
3.53.00.00.00.01.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
N/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
2.00
HoldN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3.00
Buy$7.38185.85% Upside

Current Analyst Ratings

Latest VYNE, INBP, CURR, LCI, and TXMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/29/2024
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.75
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
$4.90M1.75N/AN/A($0.09) per share-1.22
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
$50.67M0.13$0.04 per share5.75$0.63 per share0.34
Lannett Company, Inc. stock logo
LCI
Lannett
$340.58M0.00N/AN/A($23.34) per share0.00
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
$1.30M16.85N/AN/A$2.77 per share0.69
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$420K86.61N/AN/A$6.36 per share0.41

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
-$25.51MN/A0.00N/A-477.70%-621.61%-65.32%N/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
-$30K-$0.01N/AN/A-0.76%-2.05%-1.47%5/6/2024 (Estimated)
Lannett Company, Inc. stock logo
LCI
Lannett
-$231.62M-$18.88N/AN/AN/A-62.40%N/A-13.39%N/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
-$10.28MN/A0.00N/AN/A-25.54%-14.87%5/20/2024 (Estimated)
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$28.45M-$7.04N/AN/AN/A-6,710.38%-77.46%-62.93%5/9/2024 (Estimated)

Latest VYNE, INBP, CURR, LCI, and TXMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/29/2024Q4 2023
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.50-$0.20+$0.30-$0.20$0.15 million$0.08 million
2/12/2024Q2 2024
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A-$0.01-$0.01-$0.01N/A$11.51 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
N/AN/AN/AN/AN/A
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
Lannett Company, Inc. stock logo
LCI
Lannett
N/AN/AN/AN/AN/A
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
N/A
0.35
0.32
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
N/A
2.93
0.84
Lannett Company, Inc. stock logo
LCI
Lannett
N/A
2.23
1.39
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
N/A
1.72
1.72
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/A
12.73
12.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
0.19%
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
25.25%
Lannett Company, Inc. stock logo
LCI
Lannett
40.28%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
30.74%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
83.78%

Insider Ownership

CompanyInsider Ownership
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
17.80%
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
45.60%
Lannett Company, Inc. stock logo
LCI
Lannett
13.12%
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
1.20%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
1.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avenir Wellness Solutions, Inc. stock logo
CURR
Avenir Wellness Solutions
3278.17 million63.86 millionNot Optionable
Integrated BioPharma, Inc. stock logo
INBP
Integrated BioPharma
14130.10 million16.37 millionNot Optionable
Lannett Company, Inc. stock logo
LCI
Lannett
81010.77 million9.35 millionOptionable
TherapeuticsMD, Inc. stock logo
TXMD
TherapeuticsMD
111.53 million11.39 millionOptionable
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
1014.10 million13.85 millionNot Optionable

VYNE, INBP, CURR, LCI, and TXMD Headlines

SourceHeadline
VYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth PlansVYNE Therapeutics (NASDAQ:VYNE) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - April 13 at 8:27 AM
Acne Treatment Market Poised for Substantial Growth, Anticipated to Reach USD 16.2 Billion by 2032Acne Treatment Market Poised for Substantial Growth, Anticipated to Reach USD 16.2 Billion by 2032
pharmiweb.com - March 28 at 12:46 PM
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
finance.yahoo.com - March 19 at 9:08 AM
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceVYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
globenewswire.com - March 19 at 8:00 AM
Heres Why VYNE Therapeutics Inc. (VYNE) Is a Great Buy the Bottom Stock NowHere's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
zacks.com - March 13 at 10:56 AM
What Makes VYNE Therapeutics Inc. (VYNE) a New Buy StockWhat Makes VYNE Therapeutics Inc. (VYNE) a New Buy Stock
zacks.com - March 8 at 1:01 PM
Wall Street Breakfast Podcast: NYCB Gets $1B Investment BoostWall Street Breakfast Podcast: NYCB Gets $1B Investment Boost
seekingalpha.com - March 7 at 8:21 AM
VYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagVYNE Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
finance.yahoo.com - March 3 at 8:59 AM
Buy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical DevelopmentsBuy Rating on VYNE Therapeutics: Strong Financials and Promising Clinical Developments
markets.businessinsider.com - February 29 at 7:00 PM
VYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateVYNE Therapeutics Inc.: VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
finanznachrichten.de - February 29 at 10:04 AM
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business UpdateVYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
globenewswire.com - February 29 at 8:00 AM
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
finance.yahoo.com - February 27 at 8:06 AM
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific SymposiumVYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium
globenewswire.com - February 27 at 8:00 AM
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
finance.yahoo.com - February 21 at 8:16 AM
VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceVYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
globenewswire.com - February 21 at 8:00 AM
Favourable Signals For VYNE Therapeutics: Numerous Insiders Acquired StockFavourable Signals For VYNE Therapeutics: Numerous Insiders Acquired Stock
finance.yahoo.com - February 2 at 7:18 AM
Buy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial ResultsBuy Rating for VYNE Therapeutics Backed by Promising Vitiligo Drug Trial Results
markets.businessinsider.com - January 10 at 4:27 PM
Prurigo Nodularis Treatment Market Forecasts Surpassing US$ 930.9 Million by 2033-FMI StudyPrurigo Nodularis Treatment Market Forecasts Surpassing US$ 930.9 Million by 2033-FMI Study
fmiblog.com - January 4 at 12:32 AM
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of DirectorsVYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
finance.yahoo.com - January 3 at 9:29 AM
Investing in VYNE Therapeutics Inc [VYNE]: What You Must KnowInvesting in VYNE Therapeutics Inc [VYNE]: What You Must Know
knoxdaily.com - January 1 at 10:15 AM
VYNE Therapeutics says director Lepore buys 13K shares in coVYNE Therapeutics says director Lepore buys 13K shares in co
msn.com - November 20 at 3:25 PM
Cormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics IncCormorant Asset Management, LP Acquires New Stake in VYNE Therapeutics Inc
finance.yahoo.com - November 14 at 5:53 PM
VYNE Therapeutics files to sell 36.27M shares for holdersVYNE Therapeutics files to sell 36.27M shares for holders
msn.com - November 13 at 5:35 PM
VYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateVYNE Therapeutics Inc.: VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
finanznachrichten.de - November 13 at 12:34 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Avenir Wellness Solutions logo

Avenir Wellness Solutions

OTCMKTS:CURR
Avenir Wellness Solutions, Inc., through its subsidiary The Sera Labs, Inc., engages in the development of nutraceutical formulation and delivery technologies in novel dosage forms to improve efficacy and enhance wellness. It provides its products in beauty, health and wellness, and pet care categories under the Seratopical, Seratopical Revolution SeraLabs, and Nutri-Strips brand names. The company sells its products through drug and grocery chains, convenience stores, and mass retailers. It also offers its products under private label to retailers and multi-level marketers, as well as DTC, via online website orders. The company was formerly known as CURE Pharmaceutical Holding Corp. and changed its name to Avenir Wellness Solutions, Inc. in October 2022. Avenir Wellness Solutions, Inc. was founded in 2011 and is headquartered in Sherman Oaks, California.
Integrated BioPharma logo

Integrated BioPharma

OTCMKTS:INBP
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Lannett logo

Lannett

NYSE:LCI
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Trevose, PA.
TherapeuticsMD logo

TherapeuticsMD

NASDAQ:TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
VYNE Therapeutics logo

VYNE Therapeutics

NASDAQ:VYNE
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.